199 results about "TLR4" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to application of Ackerman muciniphila in preparation of diabetic metabolic disease related renal injury products. The preservation number of the ackermann muciniphile is CGMCC (China General Microbiological Culture Collection Center) No.20955. The ackermann muciniphile provided by the invention can be used for remarkably reducing the indexes of blood urea nitrogen, serum creatinine and urine protein and improving the renal function; the oxidative stress of the kidney is relieved by reducing the malondialdehyde level and improving the activity of SOD, CAT and GSH-Px; the TLR4 / NF-kappa B pathway is inhibited, TNF-alpha and IL-1beta secretion is reduced, and inflammatory response is relieved; finally, the kidney protection effect is achieved through the anti-oxidation, anti-inflammatory and anti-fibrosis effects.

The invention discloses an NF (nuclear factor)-kappa B inhibitor. The NF-kappa B inhibitor comprises N-trans-p-coumaroyl tyramine; the invention further discloses a preparation method of the NF-kappa B inhibitor. The invention also discloses an application of the NF-kappa B inhibitor in medicines for preventing or treating diseases related to body inflammation. According to the application disclosed by the invention, the influence of the N-trans-p-coumaroyl tyramine on a TLR4 / MyD88 / NF-kappa B inflammation signal channel is detected through an immunofluorescence technology, and a result shows that the N-trans-p-coumaroyl tyramine can be used for reducing the expression of TLR4 and MyD88 proteins and inhibiting the transfer of NF-kappa B proteins to cell nucleuses, so that the N-trans-p-coumaroyl tyramine can be used as an NF-kappa B inhibitor and can be used for preparing an anti-inflammatory drug. The composition is used for preventing or treating body inflammatory response.

The invention provides a traditional Chinese medicine compound for treating sicca syndrome and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compounds. The traditional Chinese medicine compound provided by the invention has the effects of eliminating dampness and heat, removing blood stasis and promoting salivation, can safely and effectively treat sicca syndrome by improving functions of exocrine glands and regulating immunity, belongs to a pure traditional Chinese medicine preparation, and has no toxic or side effect. The traditional Chinese medicine compound is proved to be capable of remarkably relieving the sicca syndrome, relieving dry mouth and eye symptoms of a patient, relieving fatigue, regulating and controlling a plurality of signals taking RAGE / TLR4 as a core, inhibiting excessive activation of an HMGB1-RAGE / TLR4-NF-kappa B pro-inflammatory pathway from gene and protein levels, inhibiting generation of pro-inflammatory cytokines, reducing inflammatory response and improving the immunity of the patient. The effect of treating the sicca syndrome is achieved. By acting on STAT3 phosphorylation, Tfh proliferation is inhibited, IL-21 secretion is reduced, humoral immune disorder is relieved, and the sicca syndrome is treated, so that the condition of the sicca syndrome is relieved, and the prognosis of the sicca syndrome is improved.

The invention discloses application of naringenin in preparation of a medicine for preventing and treating diseases caused by pseudorabies virus, and belongs to the technical field of biological medicine. The naringenin has good anti-PRV activity in vivo and in vitro. The naringenin can inhibit virus proliferation of the pseudorabies virus in an intracellular replication stage, reduce expression of PRV gB protein, lower expression of TLR4 and P65 protein to inhibit activation of an NF-kB pathway and lower expression of an inflammatory gene, and reduce nucleation of the NF-kB / P65 protein to achieve anti-inflammatory and antiviral effects. In-vivo experiments prove that naringenin can delay the disease time of mice, reduce the virus load in organs of the mice infected by PRV and relieve pathological changes of tissues and organs of the mice, and in addition, the survival rate of the mice infected by viruses is improved by adjusting the serum cell factor level of the mice. The naringenin provides a new strategy for preventing and treating PRV infection.

Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.

The invention belongs to the field of compositions, and particularly relates to an anti-colitis composition and application, the anti-colitis composition comprises bacillus natto JLNA2301 bacterial liquid and ginseng water-soluble dietary fiber; the preservation number of the bacillus natto JLNA2301 is CGMCC (China General Microbiological Culture Collection Center) No. 27770; the volume mass ratio of the bacillus natto JLNA2301 bacterial liquid to the ginseng water-soluble dietary fibers in the composition is (8-10) mL: (0.25-1) g, and the viable count of the bacillus natto JLNA2301 bacterial liquid is 1 * 10 < 8 >-1 * 10 < 10 > CFU / mL; the composition can be used for preventing and treating colon shortening and bleeding caused by ulcerative colitis, repairing intestinal barrier protein and inhibiting a TLR4 / NF-kappa B inflammation pathway; the intestinal flora structure is regulated in a prevention period and a treatment period.

Provided are a method for enhancing the immune response of a mammal and a composition comprising liposomes, a TLR4 agonist and a TLR7 agonist.

The invention belongs to the technical field of animal immunopotentiators, and particularly relates to an oil-in-water type veterinary adjuvant and a preparation method thereof. The oil-in-water type veterinary adjuvant comprises white oil, span 80, Tween 80, PEG400, astragalus polysaccharide and a phosphate buffer solution, the astragalus polysaccharide cooperates with a surfactant to activate a TLR4 / NF-kappa B pathway, Th1 / Th2 / Th17 three-way immune response is achieved, the serum IgG and mucous membrane sIgA antibody level is remarkably improved, and the problems that a traditional O / W adjuvant is high in layering rate (smaller than 5%), and the stability of the traditional O / W adjuvant is poor are solved through compound optimization of the HLB value (HLB = 11.5-12.0) of the HLB value of span 80 and Tween 80. And storage at 4 DEG C for 90 days) and poor freeze-thaw stability are solved.

The invention relates to an establishment method and application of in-vitro intestinal inflammation models of mice of different ages, and relates to the technical field of biology. According to the invention, young, adult, middle-aged and old wild type (WT) and TLR4 gene deletion type (TLR4 <- / ->) mice are selected, colon tissues are cultured in vitro, inflammatory response is induced by using interleukin-1beta (IL-1beta) stimulation, an age-related intestinal inflammation model is constructed, the inflammation phenotype of the mouse model and the activity of a TLR4 / MyD88 / NF-kappa B signaling pathway are determined by comparing WT and TLR4 <- / ->, and the age-related intestinal inflammation model is constructed. The core function of the TLR4 in regulating age-dependent intestinal barrier dysfunction is defined, a regulatory network of the TLR4 in intestinal immune aging and flora-host interaction is disclosed, and an age personalized medical strategy is promoted. According to the invention, an efficient and customizable multi-age in-vitro intestinal inflammation model is constructed, and an innovative platform is provided for mechanism analysis and intervention drug screening of TLR4 targeted therapy and age-related intestinal diseases.

The invention belongs to the technical field of food biology, and discloses an abalone-derived immunomodulatory peptide as well as a preparation method and application thereof. The abalone source immunomodulatory peptide is obtained by combining double-enzyme enzymolysis and molecular docking screening, and comprises at least one of peptides with amino acid sequences shown as SEQ.ID.NO.1-6, and the docking energy of the peptides and a receptor TLR4 is-7.4 kcal / mol,-6.9 kcal / mol,-6.8 kcal / mol,-6.8 kcal / mol,-6.8 kcal / mol and-6.6 kcal / mol in sequence respectively. Experiments prove that the abalone peptide has high immunocompetence, can provide a basis for application of the abalone-derived immunomodulatory peptide in preparation of functional food from natural food sources, and has important significance for development of novel immunomodulatory peptide products.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of Xianglian intestine decoction in preparation of a medicine for treating ulcerative colitis through a targeted TLR4 / NLRP3 / GSDMD channel. According to the invention, the TLR4 is determined as a key target, and experiments show that the active ingredients in the Xianglian intestine soup and the TLR4 have very strong binding affinity. In-vivo experiments prove that the Xianglian intestine soup down regulates the protein levels of TLR4, NLRP3 and GSDMD-N and the mRNA expression (Plt; 0.05) of IL-1beta and IL-18, so that the pyroptosis is inhibited. Furthermore, the Xianglian intestine decoction inhibits NLRP3 inflammasome activation and GSDMD-mediated pyroptosis by targeting TLR4 so as to relieve UC inflammation and intestinal barrier injury. The invention provides a mechanism insight for the clinical curative effect of the Xianglian intestine decoction for treating ulcerative colitis.

The invention relates to the technical field of medicinal chemistry, and provides a TLR4 agonist, application thereof and a vaccine composition. The TLR4 agonist is a compound with a structure as shown in a formula 1 or a pharmaceutically acceptable salt thereof, the compound is glucosamine aminoalkyl 4-phosphate series molecules derived from MPL-12 structure modification, and the series molecules have enhanced immunostimulatory activity and selective immune response induction capability.

The invention belongs to the technical field of traditional Chinese medicine research, and particularly relates to ganoderma lucidum polysaccharide and an extraction method and application thereof. The structural formula of the ganoderan is shown as a formula I in the specification. The ganoderan extracted by the invention can repair intestinal barriers by promoting the growth of beneficial intestinal bacteria, alleviate liver inflammation by targeting LPS / TLR4 / NF-kappa B / MAPK signal pathways, and reduce fat accumulation, thereby effectively alleviating the non-alcoholic fatty liver disease; and # imgabs0 #.

The invention discloses a Dunella strain, polysaccharide produced by the Dunella strain and application of the Dunella strain. The preservation number of the Duronella G3 is CCTCC (China Center For Type Culture Collection) NO: M 2024137, and the exopolysaccharide TDG3 produced by the Duronella G3 is used as a TLR4 / DC-SIGN dual receptor agonist and has the effect of remarkably reducing body weight. The exopolysaccharide TDG3 disclosed by the invention can obviously reduce the appetite of mice, reduce the food intake, reduce the body weight and reduce the content of adipose tissues, can also relieve or prevent liver fatty degeneration caused by obesity, is safe and non-toxic, is suitable for preparing the medicines for reducing fat and losing weight, and has a relatively good clinical application value and a wide application prospect.

The invention discloses application of hesperidin in preparation of a medicine for preventing and / or treating porcine contagious pleuropneumonia, and belongs to the field of biological medicine. The concentration of the hesperidin is 6.25-25 [mu] g / mL, and cell experiments prove that the hesperidin can inhibit cell inflammatory response and reduce expression of inflammatory factors, and can effectively relieve the actinobacillus pleuropneumoniae induced endovascular dermatitis injury by inhibiting activation of CD14 / TLR4-NF [kappa] B P65. Animal experiments prove that the hesperidin can relieve pathological changes and injuries of various tissues and organs after actinobacillus pleuropneumoniae infection, improve weight loss caused by actinobacillus pleuropneumoniae infection, relieve inflammatory response and metabolic dysfunction caused by actinobacillus pleuropneumoniae, and improve the body weight loss caused by actinobacillus pleuropneumoniae. The composition plays a role in protecting organisms infected by actinobacillus pleuropneumoniae. The invention provides a new scientific basis for controlling porcine contagious pleuropneumonia by using natural medicines.

The application discloses a virtual screening method of a small-molecule compound targeting TLR4. The application screens potential compounds capable of combining with TLR4 through three-dimensional molecular docking, and preliminarily proves that three compounds, Z1410232649, F27210326 and HY-N0029, have better TLR4 inhibiting effects through experimental verification. Among them, Z1410232649 performs most outstandingly, can significantly inhibit the release of inflammatory factors IL-6, TNF-alpha and IFN-gamma induced by LPS, and can be used as a novel anti-inflammatory drug or immunotherapy drug targeting TLR4.

The invention discloses a Chinese forest frog peptide or a salt thereof. The Chinese forest frog peptide comprises an amino acid sequence Asn-Pro-Asp-Tyr-Arg as shown in SEQ ID NO: 1. Moisturizing and relieving mechanisms of the peptide are explored through molecular docking, and we find that the Chinese forest frog peptide as shown in SEQ ID NO: 1 can be effectively docked with hyaluronidase and TLR4-MD2. According to the present invention, chemical synthesis and activity evaluation are performed on the Chinese forest frog peptide Asn-Pro-Asp-Tyr-Arg (NPDYR) represented by SEQ ID NO: 1, and the Chinese forest frog peptide shows certain repairing, moisturizing and soothing activities, can be used as a functional component in cosmetics, and has good application prospects.

The invention provides application of PRP-Exos in preparation of a medicine for treating neuropathic pain, and relates to the technical field of clinical medicine. According to the invention, the treatment effect of PRP-Exos on neuropathic pain by inhibiting a TLR4 / NF-kappa B signal channel is clarified, a new thought is provided for clinical transformation, meanwhile, an intrathecal injection delivery mode is adopted, the limitation of low bioavailability of peripheral administration is overcome, meanwhile, the treatment effect is comprehensively verified through a behavioral-histological-molecular biological multi-modal evaluation system, and the application prospect is wide. The potential of the PRP-Exos in relieving the neuropathic pain is proved.

This invention provides the use of Yigongsan in the treatment of myelodysplastic syndrome (MDS). Specifically, this invention has found that Yigongsan improves ineffective hematopoiesis in MDS patients and significantly alleviates traditional Chinese medicine symptoms of MDS, such as fatigue, lethargy, lack of thirst, and sallow complexion. Furthermore, it has been discovered that Yigongsan regulates hematopoietic function in MDS through the S100A9-TLR4-NF-κB signaling pathway. This invention also provides a treatment method for MDS.

The invention discloses a manganese-based nano-enzyme composite material as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing Mn3O4-PVP from Mn3O4 NPs and PVP10, and then loading the Mn3O4-PVP into a ZIF-8 structure in the process that Zn < 2 + > and 2-MI react to form ZIF-8, so as to obtain Mn3O4-coated ZIF-8 NPs; (2) covering the surface of the Mn3O4 ZIF-8 with HA through ion coordination, and synthesizing MZH; and (3) carrying out clathration on MZH through ES100, and synthesizing MZH coated ES100. By inhibiting a TLR4 / NF-kappa B pathway, activating an Nfr2 / Keap1 pathway and increasing expression of intestinal tight junction protein, mouse colitis induced by DSS is resisted, and symptoms of the mouse colitis are relieved.

The application discloses application of Bifidobacterium longum exopolysaccharide or a co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and probiotics in improving inflammation. The application finds that the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can inhibit LPS-induced TLR4 / NfkB (P65) signal path activation, inhibit the polarization of macrophages from M0 to M1, thereby inhibiting inflammatory reactions, and the inhibiting effect of the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus is more obvious. Therefore, the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can be used for preparing drugs for inhibiting inflammatory reactions, and are helpful to the treatment of immune and chronic inflammatory diseases and the development of related drugs.

The invention discloses an application of rare ginsenoside in preparation of a medicine for improving intestinal dysbacteriosis and inhibiting rheumatoid arthritis, including an application of rare ginsenoside Rk3 in preparation of a medicine for improving intestinal dysbacteriosis and an application of rare ginsenoside Rk3 in preparation of a medicine for inhibiting rheumatoid arthritis. Rare ginsenoside Rk3 can improve the richness and diversity of intestinal flora of mice with rheumatoid arthritis, enrich probiotics and regulate bile acid metabolism, so that intestinal flora imbalance caused by rheumatoid arthritis is effectively relieved, and intestinal barrier function damage is repaired; the generation of inflammatory factors can be reduced, a TLR4-NF-kappa B signal channel is inhibited, and joint injury in an RA model is treated. Based on investigation of causal association among ginsenoside Rk3, intestinal flora and rheumatoid arthritis, clinical application of rare ginsenoside Rk3 in rheumatoid arthritis is provided, and new strategies and candidate drugs are provided for treatment of rheumatoid arthritis.

The application discloses an application of a TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, relates to the technical field of biology and medicine, and discloses an application of the TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, wherein the TLR4 / NF-kappa B signal path inhibitor is Danggui Buxue Decoction; the Danggui Buxue Decoction is composed of Astragalus and Angelica with a mass ratio of 5:1; the TLR4 / NF-kappa B signal path inhibitor is used for down-regulating expression of TLR4 protein and NF-kappa B protein in liver tissue; the improvement of hematopoietic function of anemic inflammatory includes increasing peripheral blood red blood cell count, white blood cell count, platelet count and hemoglobin level; the Danggui Buxue Decoction is used as the TLR4 / NF-kappa B inhibitor to improve anemic inflammatory, can down-regulate TLR4 / NF-kappa B expression, improve blood cells and hemoglobin, improve bone marrow pathology, reduce inflammatory factors and hepcidin, increase iron content, and provide a corresponding curative effect evaluation method, and provides a new choice for anemic inflammatory treatment.

The invention discloses application of tenuifolin in preparation of a medicine for treating multiple sclerosis, and belongs to the technical field of biological pharmacy. Aiming at the problem that the treatment effect and the specific action mechanism of TEN on the multiple sclerosis disease are not clear yet, an EAE model group of a mouse is used for simulating the multiple sclerosis disease, meanwhile, a TEN intervention group is set for simulating the multiple sclerosis disease and then TEN intervention is carried out, and it can be found through experimental comparison that compared with mice of the EAE model group, the mice of the TEN intervention group are more obvious in effect. The average neurological function score is obviously reduced, the clinical symptoms and the demyelination degree are alleviated, the MBP expression is increased, and the inflammatory infiltration is reduced; in addition, TEN intervention can significantly reduce the increase of TLR4 / NF-kappa B protein in mouse spinal cord tissues of an EAE model group. The TEN can inhibit activation of a TLR4 / NF-kappa B pathway to effectively relieve demyelination and abnormal behaviors of mice of an EAE model group and slow down inflammatory response, so that the TEN plays a role in treating the mice of the EAE model group.

The invention belongs to the technical field of novel application of nattokinase, and provides application of nattokinase in preparation of a medicine for preventing and / or treating Parkinson's disease. According to the invention, an MPTP / MPP + induced Parkinson's disease (PD) in-vivo and in-vitro model is established, and a neuroprotection mechanism of nattokinase is disclosed by adopting a systematic experiment method. Results show that the nattokinase can significantly improve dyskinesia and intestinal dysfunction of MPTP-induced PD mice; the damage of dopaminergic neurons of the middle brain is effectively relieved, and the density of tyrosine hydroxylase positive neurons is maintained; the expression of TLR4 and NLRP3 inflammasome pathways and related proinflammatory cytokines is inhibited, and the neuroinflammatory response is relieved; pINK1 / Parkin expression is up-regulated, mitochondrial autophagy is activated, and damaged neurons are cleared. Direct association between nattokinase and Parkinson's disease prevention and treatment is established for the first time, an innovative solution is provided for developing a novel anti-Parkinson's disease medicine with dual effects of motor function improvement and neuroprotection, and the application has important development value in the field of treatment of neurodegenerative diseases.

The invention belongs to the field of polypeptides, and particularly relates to a TLR4 binding peptide and application thereof. The specific technical scheme is as follows: the nucleotide sequence of the polypeptide is edited as shown in SEQ ID NO: 1. The binding peptide containing 67 amino acids is screened out, is good in solubility, can be stably bound with TLR4, and is expected to become a new medicine for treating or relieving pain including chronic pain. The polypeptide can also be prepared into health care products, special medical foods and the like with the function of treating or relieving pain according to actual conditions.

The present disclosure relates to the use of compound (I) and any of its salts for the treatment of a neoplasm characterized by high expression of toll-like receptor 4 (TLR4) in the tumor or its microenvironment, associated with at least one of the pathophysiological complications including immunosuppression, angiogenesis, fibrosis, or metastasis.

The invention provides lactobacillus plantarum S7-12, fermented vegetables and application of the lactobacillus plantarum S7-12 and the fermented vegetables, and belongs to the technical field of microbial fermentation, the lactobacillus plantarum S7-12 is preserved in Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No: 66578. The plant lactobacillus S7-12 has relatively strong growth ability, acid production ability, acid resistance and salt resistance, and fermented vegetables prepared from the plant lactobacillus S7-12 can be used for relieving weight loss and colon shortening caused by inflammatory bowel diseases, reducing disease activity indexes and visceral organ indexes, relieving intestinal mucosa structural damage, relieving oxidative stress injury of colon, and improving the immunity of the vegetables. The release of proinflammatory factors in serum and colon is reduced, the secretion of anti-inflammatory factors is improved, the expression quantity of colon tight junction protein is increased, the TLR4 pathway is activated, and the colon barrier function is improved; the method can be used for preparing health-care foods or medicines, and has a wide application prospect.

Stable aqueous formulations of adjuvant comprising a TLR7 / 8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.